» Articles » PMID: 17562708

Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2007 Jun 15
PMID 17562708
Citations 190
Authors
Affiliations
Soon will be listed here.
Abstract

Tau in Alzheimer disease brain is highly phosphorylated and aggregated into paired helical filaments comprising characteristic neurofibrillary tangles. Here we have analyzed insoluble Tau (PHF-tau) extracted from Alzheimer brain by mass spectrometry and identified 11 novel phosphorylation sites, 10 of which were assigned unambiguously to specific amino acid residues. This brings the number of directly identified sites in PHF-tau to 39, with an additional six sites indicated by reactivity with phosphospecific antibodies to Tau. We also identified five new phosphorylation sites in soluble Tau from control adult human brain, bringing the total number of reported sites to nine. To assess which kinases might be responsible for Tau phosphorylation, we used mass spectrometry to determine which sites were phosphorylated in vitro by several kinases. Casein kinase 1delta and glycogen synthase kinase-3beta were each found to phosphorylate numerous sites, and each kinase phosphorylated at least 15 sites that are also phosphorylated in PHF-tau from Alzheimer brain. A combination of casein kinase 1delta and glycogen synthase kinase-3beta activities could account for over three-quarters of the serine/threonine phosphorylation sites identified in PHF-tau, indicating that casein kinase 1delta may have a role, together with glycogen synthase kinase-3beta, in the pathogenesis of Alzheimer disease.

Citing Articles

Improving vulnerable Calbindin1 neurons in the ventral hippocampus rescues tau-induced impairment of episodic memory.

Lei H, Lv J, Zhang F, Wei L, Shi K, Liu J Transl Neurodegener. 2025; 14(1):12.

PMID: 40038800 PMC: 11877784. DOI: 10.1186/s40035-025-00473-w.


Brain phosphoproteomic analysis identifies diabetes-related substrates in Alzheimer's disease pathology in older adults.

Capuano A, Sarsani V, Tasaki S, Mehta R, Li J, Ahima R Alzheimers Dement. 2024; 21(2):e14460.

PMID: 39732516 PMC: 11848201. DOI: 10.1002/alz.14460.


Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer's disease.

Bryan Iii M, Tian X, Tseng J, Evangelista B, Ragusa J, Bryan A Acta Neuropathol Commun. 2024; 12(1):163.

PMID: 39396065 PMC: 11470691. DOI: 10.1186/s40478-024-01865-1.


Characterization of Olive Oil Phenolic Extracts and Their Effects on the Aggregation of the Alzheimer's Amyloid-β Peptide and Tau.

Alaziqi B, Beckitt L, Townsend D, Morgan J, Price R, Maerivoet A ACS Omega. 2024; 9(30):32557-32578.

PMID: 39100310 PMC: 11292642. DOI: 10.1021/acsomega.4c01281.


Tau protein profiling in tauopathies: a human brain study.

Lantero-Rodriguez J, Camporesi E, Montoliu-Gaya L, Gobom J, Piotrowska D, Olsson M Mol Neurodegener. 2024; 19(1):54.

PMID: 39026372 PMC: 11264707. DOI: 10.1186/s13024-024-00741-9.